Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-24, Stock:LLY, The news for the past five days is as follows:
2018-12-17: NEWS1: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS2: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS3: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS4: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS5: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS6: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS7: 7 Major Pharmaceutical Stocks to Quarantine Now.NEWS8: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS9: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS10: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS11: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS12: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS13: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS14: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS15: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS16: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS17: Dow Jones Futures: The Worst Part About This Stock Market Rally.NEWS18: Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial.NEWS19: Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis.NEWS20: Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study.NEWS21: Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study.
2018-12-18: NEWS1: Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies.NEWS2: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS3: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS4: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS5: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS6: iShares Core High Dividend ETF Experiences Big Inflow.NEWS7: iShares Core High Dividend ETF Experiences Big Inflow.NEWS8: A Look At The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY).NEWS9: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS10: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS11: Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB.NEWS12: Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB.NEWS13: Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis.NEWS14: Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint.NEWS15: Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint.NEWS16: Elanco Initiates 2019 Guidance - Quick Facts.NEWS17: Elanco Initiates 2019 Guidance - Quick Facts.
2018-12-19: NEWS1: Eli Lilly CEO on winning in migraine treatments: 'It's a horse race between three great companies'.NEWS2: Close Update: Stocks Tumble Giving Up Early Gains After Fed Raises Interest Rates.NEWS3: Close Update: Stocks Tumble Giving Up Early Gains After Fed Raises Interest Rates.NEWS4: Top-Rated Pharma Stock Pops On Better-Than-Expected 2019 Outlook.NEWS5: ADIL On The Job, ADRO Teams Up With LLY, So Long CIVI.NEWS6: ADIL On The Job, ADRO Teams Up With LLY, So Long CIVI.NEWS7: Daily Dividend Report: LLY, TWO, SHO, SRE, FCX, MAS.NEWS8: Daily Dividend Report: LLY, TWO, SHO, SRE, FCX, MAS.NEWS9: Why Eli Lilly Stock Is Still Shining in the Darkness.NEWS10: Why Eli Lilly Stock Is Still Shining in the Darkness.NEWS11: Eli Lilly Forecast Points to a Strong Year.NEWS12: Mid-Day Update: Wall Street Set For Rate Hike in Dovish Wrapping.NEWS13: Mid-Day Update: Wall Street Set For Rate Hike in Dovish Wrapping.NEWS14: Aduro Stock Surges on STING Activator Deal With Eli Lilly.NEWS15: Aduro Stock Surges on STING Activator Deal With Eli Lilly.NEWS16: Eli Lilly Shares Jump After Dividend Boost, Robust 2019 Outlook.NEWS17: Why Eli Lilly Stock Is Still Shining in the Darkness.NEWS18: Aduro Stock Surges on STING Activator Deal With Eli Lilly.NEWS19: Eli Lilly sees 2019 profit, revenue above estimates; shares rise.NEWS20: Eli Lilly Leaps, General Mills Jumps, and 6 More Wednesday Morning Movers.NEWS21: UPDATE 1-Eli Lilly forecasts 2019 profit, revenue above estimates.NEWS22: Stocks making the biggest moves premarket: GIS, UAA, FDX, FB, JNJ & more.NEWS23: Eli Lilly Pulls Back Off Best Levels But Remains Firmly Positive.NEWS24: Eli Lilly Pulls Back Off Best Levels But Remains Firmly Positive.NEWS25: Eli Lilly&apos;s stock gains after upbeat profit and revenue outlook, raised dividend.NEWS26: Eli Lilly forecasts 2019 profit above estimates.NEWS27: Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting.NEWS28: Lilly Announces 15 Percent Dividend Increase.NEWS29: Lilly Sees FY19 Results Above View; Hikes Dividend.NEWS30: Lilly Sees FY19 Results Above View; Hikes Dividend.
2018-12-20: NEWS1: Lilly's Shares Rise on Robust 2019 View, Dividend Hike.NEWS2: Allergan Drops, Stops Textured Breast Implant Sales in Europe.NEWS3: Allergan Drops, Stops Textured Breast Implant Sales in Europe.NEWS4: Supernus Pharma's ADHD drug meets main goal in study on adolescents.NEWS5: Allergan Drops, Stops Textured Breast Implant Sales in Europe.NEWS6: Company News For Dec 20, 2018.NEWS7: Company News For Dec 20, 2018.NEWS8: The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab.NEWS9: Eli Lilly and Pfizer Are Boosting Dividends.NEWS10: Company News For Dec 20, 2018.NEWS11: Eli Lilly CEO on drug prices: Patients are paying too much out-of-pocket costs.NEWS12: Eli Lilly's Technical Setup Looks So-So, So Be Ready to Take Action.NEWS13: Eli Lilly Technical Setup Looks So-So, So Be Ready to Take Action.NEWS14: Top Analyst Reports for Eli Lilly, Mitsubishi UFJ & Thermo Fisher.NEWS15: Top Analyst Reports for Eli Lilly, Mitsubishi UFJ & Thermo Fisher.NEWS16: Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18).NEWS17: Eli Lilly CEO talks winning on migraine treatments.NEWS18: 'It's a horse race between three great companies': Eli Li....NEWS19: Cramer Remix: If you can handle the allegations, these companies could be profitable long-term plays.NEWS20: Cramer Remix: If you can handle the allegations, these companies could be profitable long-term plays.
2018-12-21: NEWS1: Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study.NEWS2: Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study.NEWS3: Interesting LLY Put And Call Options For March 2019.NEWS4: Interesting LLY Put And Call Options For March 2019.NEWS5: Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study.NEWS6: Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations.NEWS7: Lilly's Shares Rise on Robust 2019 View, Dividend Hike.NEWS8: Lilly's Shares Rise on Robust 2019 View, Dividend Hike.

Answer: Decrease